Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909)

被引：0

作者：

Jung, Sung-Hoon ^{[1
]}

Min, Chang-Ki ^{[2
]}

Lee, Jae Hoon ^{[3
]}

Mun, Yeung-Chul ^{[4
]}

Bang, Soo-Mee ^{[5
]}

Yoon, Dok Hyun ^{[6
]}

Lee, Ho Sup ^{[7
]}

Kim, Kihyun ^{[8
]}

Lee, Je-Jung ^{[1
]}

机构：

[1] Chonnam Natl Univ, Hwasun Hosp, Chonnam Natl Univ Med Sch, Dept Hematol Oncol, Hwasun, South Korea

[2] Catholic Univ Korea, Seoul St Marys Hematol Hosp, Seoul, South Korea

[3] Gachon Univ, Gil Med Ctr, Incheon, South Korea

[4] Ewha Womans Univ, Sch Med, Seoul, South Korea

[5] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea

[6] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[7] Kosin Univ, Gospel Hosp, Busan, South Korea

[8] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

来源：

BONE MARROW TRANSPLANTATION | 2022年 / 57卷 / 12期

关键词：

PROGRESSION; MANAGEMENT; THERAPY; SCT;

D O I：

10.1038/s41409-022-01818-z

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

The effectiveness of early treatment for biochemical relapse of multiple myeloma (MM) is unclear. To clarify this issue, this retrospective study was performed to evaluate the survival outcomes of 315 patients with relapsed MM after upfront autologous stem cell transplantation (ASCT). Over a median follow-up of 66.6 months (range, 15.1-195.5 months), 48.2% of patients showed biochemical relapse, 41.3% showed clinical relapse, and 10.5% showed significant biochemical relapse. Progression-free survival (PFS) and overall survival (OS) were inferior for patients with clinical relapse compared to the other patients. Multivariate analysis showed that clinical relapse was an independent prognostic factor for OS. In patients with biochemical relapse, there was no significant difference in survival between patients treated while asymptomatic and those treated once clinical symptoms had appeared. Relapse type after upfront ASCT was a significant prognostic factor in patients with MM. In addition, no survival benefit of early treatment at biochemical relapse was observed, but a triplet regimen may be beneficial for MM patients with biochemical relapse.

引用

页码：1797 / 1802

页数：6

共 16 条

[1] Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study [J].

Cavo, Michele ;

Gay, Francesca ;

Beksac, Meral ;

Pantani, Lucia ;

Petrucci, Maria Teresa ;

Dimopoulos, Meletios A. ;

Dozza, Luca ;

van der Holt, Bronno ;

Zweegman, Sonja ;

Oliva, Stefania ;

van der Velden, Vincent H. J. ;

Zamagni, Elena ;

Palumbo, Giuseppe A. ;

Patriarca, Francesca ;

Montefusco, Vittorio ;

Galli, Monica ;

Maisnar, Vladimir ;

Gamberi, Barbara ;

Hansson, Markus ;

Belotti, Angelo ;

Pour, Ludek ;

Ypma, Paula ;

Grasso, Mariella ;

Croockewit, Alexsandra ;

Ballanti, Stelvio ;

Offidani, Massimo ;

Vincelli, Iolanda D. ;

Zambello, Renato ;

Liberati, Anna Marina ;

Andersen, Niels Frost ;

Broijl, Annemiek ;

Troia, Rossella ;

Pascarella, Anna ;

Benevolo, Giulia ;

Levin, Mark-David ;

Bos, Gerard ;

Ludwig, Heinz ;

Aquino, Sara ;

Morelli, Anna Maria ;

Wu, Ka Lung ;

Boersma, Rinske ;

Hajek, Roman ;

Durian, Marc ;

Borne, Peter A. von dem ;

di Toritto, Tommaso Caravita ;

Zander, Thilo ;

Specchia, Giorgina ;

Waage, Anders ;

Gimsing, Peter ;

Mellqvist, Ulf-Henrik .

LANCET HAEMATOLOGY, 2020, 7 (06) :E456-E468

[2] Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond [J].

Chim, C. S. ;

Kumar, S. K. ;

Orlowski, R. Z. ;

Cook, G. ;

Richardson, P. G. ;

Gertz, M. A. ;

Giralt, S. ;

Mateos, M. V. ;

Leleu, X. ;

Anderson, K. C. .

LEUKEMIA, 2018, 32 (02) :252-262

[3] Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Dimopoulos, M. A. ;

Moreau, P. ;

Terpos, E. ;

Mateos, M., V ;

Zweegman, S. ;

Cook, G. ;

Delforge, M. ;

Hajek, R. ;

Schjesvold, F. ;

Cavo, M. ;

Goldschmidt, H. ;

Facon, T. ;

Einsele, H. ;

Boccadoro, M. ;

San-Miguel, J. ;

Sonneveld, P. ;

Mey, U. .

ANNALS OF ONCOLOGY, 2021, 32 (03) :309-322

[4] Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma [J].

Fernandez de Larrea, C. ;

Jimenez, R. ;

Rosinol, L. ;

Gine, E. ;

Tovar, N. ;

Cibeira, M. T. ;

Fernandez-Aviles, F. ;

Martinez, C. ;

Rovira, M. ;

Blade, J. .

BONE MARROW TRANSPLANTATION, 2014, 49 (02) :223-227

[5]

Katodritou E, 2018, ANN HEMATOL, V97, P1671, DOI 10.1007/s00277-018-3361-2

[6] Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients [J].

Kumar, S. K. ;

Dispenzieri, A. ;

Lacy, M. Q. ;

Gertz, M. A. ;

Buadi, F. K. ;

Pandey, S. ;

Kapoor, P. ;

Dingli, D. ;

Hayman, S. R. ;

Leung, N. ;

Lust, J. ;

McCurdy, A. ;

Russell, S. J. ;

Zeldenrust, S. R. ;

Kyle, R. A. ;

Rajkumar, S. V. .

LEUKEMIA, 2014, 28 (05) :1122-1128

[7] Improved survival in multiple myeloma and the impact of novel therapies [J].

Kumar, Shaji K. ;

Rajkumar, S. Vincent ;

Dispenzieri, Angela ;

Lacy, Martha Q. ;

Hayman, Suzanne R. ;

Buadi, Francis K. ;

Zeldenrust, Steven R. ;

Dingli, David ;

Russell, Stephen J. ;

Lust, John A. ;

Greipp, Philip R. ;

Kyle, Robert A. ;

Gertz, Morie A. .

BLOOD, 2008, 111 (05) :2516-2520

[8] Drug therapy: Multiple myeloma [J].

Kyle, RA ;

Rajkumar, SV .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (18) :1860-1873

[9] Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group [J].

Laubach, J. ;

Garderet, L. ;

Mahindra, A. ;

Gahrton, G. ;

Caers, J. ;

Sezer, O. ;

Voorhees, P. ;

Leleu, X. ;

Johnsen, H. E. ;

Streetly, M. ;

Jurczyszyn, A. ;

Ludwig, H. ;

Mellqvist, U-H ;

Chng, W-J ;

Pilarski, L. ;

Einsele, H. ;

Hou, J. ;

Turesson, I. ;

Zamagni, E. ;

Chim, C. S. ;

Mazumder, A. ;

Westin, J. ;

Lu, J. ;

Reiman, T. ;

Kristinsson, S. ;

Joshua, D. ;

Roussel, M. ;

O'Gorman, P. ;

Terpos, E. ;

McCarthy, P. ;

Dimopoulos, M. ;

Moreau, P. ;

Orlowski, R. Z. ;

Miguel, J. S. ;

Anderson, K. C. ;

Palumbo, A. ;

Kumar, S. ;

Rajkumar, V. ;

Durie, B. ;

Richardson, P. G. .

LEUKEMIA, 2016, 30 (05) :1005-1017

[10] Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study [J].

Mina, Roberto ;

Belotti, Angelo ;

Petrucci, Maria Teresa ;

Zambello, Renato ;

Capra, Andrea ;

Di Lullo, Giacomo ;

Ronconi, Sonia ;

Pescosta, Norbert ;

Grasso, Mariella ;

Monaco, Federico ;

Cellini, Claudia ;

Gobbi, Marco ;

Ballanti, Stelvio ;

de Fabritiis, Paolo ;

Mosca-Siez, Maria Letizia ;

Marchetti, Monia ;

Liberati, Anna Marina ;

Offidani, Massimo ;

Giuliani, Nicola ;

Ria, Roberto ;

Musto, Pellegrino ;

Romano, Alessandra ;

Sonneveld, Pieter ;

Boccadoro, Mario ;

Larocca, Alessandra .

BLOOD CANCER JOURNAL, 2020, 10 (05)

← 1 2 →